The use of animal testing has significant benefits in medical research; however, increased costs, extremely high failure rates, and delays in drug approval have led many to re-evaluate its value in drug development.
Respivant Sciences announced has dosed the first patient in the SCENIC trial, a Phase 2b study of RVT-1601 for the treatment of persistent cough in patients with idiopathic pulmonary fibrosis (IPF).
The device is smaller than a microscope glass slide. It contains six tiny chambers; every two are connected by microchannels with a series of port inlets and valves.